![Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions | Business Wire Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions | Business Wire](https://mms.businesswire.com/media/20211206005829/en/933123/23/Aerie_Full_Color_Horizontal_%C2%AELogo_2019JUL20_F_%282%29.jpg)
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions | Business Wire
![Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of](https://www.sec.gov/Archives/edgar/data/1337553/000119312521219618/g181545ex99_1s1g1.jpg)
Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of
![Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease | Business Wire Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease | Business Wire](https://mms.businesswire.com/media/20220524005496/en/1465125/23/AERI.jpg)
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease | Business Wire
![Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.](https://www.sec.gov/Archives/edgar/data/1337553/000119312520264340/g91227ex99_1s1g1.jpg)
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
![Aerie Pharmaceuticals (Nasdaq: AERI) cleared to begin clinical testing for dry eye treatment - Triangle Business Journal Aerie Pharmaceuticals (Nasdaq: AERI) cleared to begin clinical testing for dry eye treatment - Triangle Business Journal](https://media.bizj.us/view/img/10299899/aerie-pharmaceuticals-research-laboratory*1200xx4032-3024-0-0.jpg)
Aerie Pharmaceuticals (Nasdaq: AERI) cleared to begin clinical testing for dry eye treatment - Triangle Business Journal
![Aerie Pharmaceuticals Inc - Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before Aerie Pharmaceuticals Inc - Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before](https://www.sec.gov/Archives/edgar/data/1337553/000119312522002144/g275498ex99_1p2g1.jpg)
Aerie Pharmaceuticals Inc - Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before
Aerie Pharmaceuticals Using ROCK Inhibitors to Change Glaucoma Management | Ophthalmology Innovation Source
![Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.](https://www.sec.gov/Archives/edgar/data/1337553/000119312520264340/g91227ex99_1s2g1.jpg)
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
![Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions — Duke OTC Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions — Duke OTC](https://otc.duke.edu/wp-content/uploads/2022/08/Aerie-Pharmaceuticals-Logo-1.png)
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions — Duke OTC
![Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of](https://www.sec.gov/Archives/edgar/data/1337553/000119312521294157/g205431ex99_1p1g1.jpg)
Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of
![Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union | Business Wire Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union | Business Wire](https://mms.businesswire.com/media/20201113005354/en/736961/22/Aerie_Logo_Updated__July_2019.jpg)
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union | Business Wire
![Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% | Business Wire Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% | Business Wire](https://mms.businesswire.com/media/20210111005071/en/851005/23/Aerie_Full_Color_Horizontal_%C2%AELogo_2019JUL20_F.jpg)